NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

|  |  |
| --- | --- |
| **1.** | **Notifying Member:** PHILIPPINES**If applicable, name of local government involved (Article 3.2 and 7.2):**  |
| **2.** | **Agency responsible:** DR. OSCAR G. GUTTIERREZ, MPAOfficer-in-Charge, Director GeneralFood and Drug AdministrationDEPARTMENT OF HEALTH**Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:** Director IVCenter for Cosmetics and Household/Urban Hazardous Substances Regulation and ResearchFood and Drug AdministrationDEPARTMENT OF HEALTHContact: (02) 8815-9600Email: cchuhsrr-policy@fda.gov.ph[www.fda.gov.ph](http://www.fda.gov.ph)  |
| **3.** | **Notified under Article 2.9.2 [****X],** **2.10.1 [****],** **5.6.2 [****],** **5.7.1 [****], 3.2 [****], 7.2 [****],** **other****:**  |
| **4.** | **Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):** Cosmetics. Toiletries (ICS code(s): 71.100.70) |
| **5.** | **Title, number of pages and language(s) of the notified document:** "Updated Guidelines on Product Information File (PIF) for Cosmetic Products Repealing FDA Circular No. 2018-001 "Reiterating the Mandatory Implementation of Article 8 of the ASEAN Cosmetic Directive 'Product Information'""; (13 page(s), in English) |
| **6.** | **Description of content:** This circular shall cover all cosmetic establishments duly licensed by the CCHUHSRR who are holders of a valid Certificate of Product Notification (CPN). |
| **7.** | **Objective and rationale, including the nature of urgent problems where applicable:** Protection of human health or safety |
| **8.** | **Relevant documents:** * Department of Health (DOH) Administrative Orders (AO) No. 2005-0015 and 2005-0025
* FDA Memorandum Circular (FMC) No. 2015-011
* FDA Circular No. 2018-001 and FDA Advisory No. 2022-0383
 |
| **9.** | **Proposed date of adoption:** Fifteen (15) days after publication in a newspaper of general circulation and filing with the University of the Philippines, Office of the National Administrative Register**Proposed date of entry into force:** Fifteen (15) days after publication in a newspaper of general circulation and filing with the University of the Philippines, Office of the National Administrative Register |
| **10.** | **Final date for comments:** 11 August 2022 |
| **11.** | **Texts available from: National enquiry point [****]** **or address, telephone and fax numbers and email and website addresses, if available, of other body:** Mr. Neil P. CatajayDirectorBureau of Philippine StandardsDepartment of Trade and Industry3F Trade and Industry Building361 Sen. Gil Puyat AvenueMakati CityPhilippinesTel: (632) 751 4700; (632) 7913128Email: bps@dti.gov.phWebsite: <http://www.bps.dti.gov.ph><https://www.fda.gov.ph/wp-content/uploads/2022/07/Draft-for-Comments-Updated-Guidelines-on-PIF.pdf><https://members.wto.org/crnattachments/2022/TBT/PHL/22_5468_00_e.pdf> |